Clinical trial • Phase III • Oncology

bevacizumab for Peritoneal metastases of colorectal cancer

Phase III trial of bevacizumab for Peritoneal metastases of colorectal cancer. 13 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Peritoneal metastases of colorectal cancer
Trial Stage
Phase III
Drug Modality
Monoclonal antibody|Diagnostic agent

Key dates

Initial CTIS Submission Date
07-10-2024
First CTIS Authorization Date
29-10-2024

Trial design

Phase III trial across 1 site in Netherlands.

Target Sample Size
13

Eligibility

Recruits 13 Vulnerable population not selected; no details on consent or assent provided in the record..

Vulnerable Population
Vulnerable population not selected; no details on consent or assent provided in the record.

Recruitment

Planned Sample Size
13
Recruitment Window Months
42

Geography

Total Number Of Sites
1
Total Number Of Participants
13

Netherlands

Earliest CTIS Part Ii Submission Date
24-10-2024
Latest Decision Or Authorization Date
29-10-2024
Processing Time Days
5
Number Of Sites
1
Number Of Participants
13

Sites

Site Name
UMCG
Department Name
Surgery
Contact Person Name
Femke van der Zant
Contact Person Email
f.a.van.der.zant@umcg.nl
Number Of Participants
13

Sponsor

Primary sponsor

Full Name
Universitair Medisch Centrum Groningen
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Investigational products

Investigational Product Name
bevacizumab-800CW (VEGF-targeted optical fluorescent imaging tracer)
Active Substance
bevacizumab
Modality
Monoclonal antibody|Diagnostic agent

Related trials

Other published trials that may interest you.